SCHEMBL6765262

SCHEMBL6765262

COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2c(Cl)cn[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.64
CRBN Q96SW2 1/20 0.36
SGK1 O00141 6/20 0.35
ERBB2 P04626 1/20 0.33
CCNE2 O96020 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
PADI4 Q9UM07 1/20 0.32
PIP4K2A P48426 1/20 0.32
PIP4K2B P78356 1/20 0.32
RORC P51449 1/20 0.31
MET P08581 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2489644 0.84 CYP3A4 (0.73) CYP3A4CRBNERBB2PADI4PIP4K2A
SCHEMBL2489645 0.84 CYP3A4 (0.73) CYP3A4CRBNERBB2PADI4PIP4K2A
SCHEMBL1764618 0.83 CYP3A4 (0.65) CYP3A4CRBNPADI4PIP4K2APIP4K2B
SCHEMBL1764614 0.83 CYP3A4 (0.65) CYP3A4CRBNPADI4PIP4K2APIP4K2B
SCHEMBL2488809 0.83 CYP3A4 (0.43) CYP3A4SGK1CCNE2CCNE1CDK2
SCHEMBL2488811 0.83 CYP3A4 (0.43) CYP3A4SGK1CCNE2CCNE1CDK2
SCHEMBL2489282 0.82 CYP3A4 (0.68) CYP3A4CRBNSGK1ERBB2PADI4
SCHEMBL2489284 0.82 CYP3A4 (0.68) CYP3A4CRBNSGK1ERBB2PADI4
SCHEMBL1542848 0.81 CYP3A4 (0.76) CYP3A4CRBNERBB2PADI4
SCHEMBL2130293 0.81 CYP3A4 (0.76) CYP3A4CRBNERBB2PADI4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 CYP3A4 978/4885CRBN 1341/4885SGK1 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.